Proteome Characteristics of Non-Alcoholic Steatohepatitis Liver Tissue and Associated Hepatocellular Carcinomas
暂无分享,去创建一个
H. Wanibuchi | N. Kawada | H. Fujii | V. Stefanov | K. Kawai | Naomi Ishii | T. Okuno | A. Kakehashi
[1] O. Yokosuka,et al. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. , 2015, World journal of gastroenterology.
[2] Takafumi Suzuki,et al. Molecular basis of the Keap1-Nrf2 system. , 2015, Free radical biology & medicine.
[3] Aijaz Ahmed,et al. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[4] N. Chavez-Tapia,et al. The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease. , 2015, Annals of hepatology.
[5] A. Ascensão,et al. Endoplasmic Reticulum Stress Response in Non-alcoholic Steatohepatitis: The Possible Role of Physical Exercise. , 2015, Metabolism: clinical and experimental.
[6] E. van Marck,et al. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. , 2015, Journal of hepatology.
[7] T. Duarte,et al. The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism , 2015, BioMed research international.
[8] T. Okanoue,et al. Influence of lifestyle‐related diseases and age on the development and progression of non‐alcoholic fatty liver disease , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.
[9] M. Ziol,et al. Keratins 8 and 18 are type II acute‐phase responsive genes overexpressed in human liver disease , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[10] J. Moreaux,et al. Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia , 2015, Journal of Hematology & Oncology.
[11] Philippe Lefebvre,et al. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. , 2015, Journal of hepatology.
[12] M. Zannini,et al. NRIP1/RIP140 siRNA-mediated attenuation counteracts mitochondrial dysfunction in Down syndrome. , 2014, Human molecular genetics.
[13] T. Mak,et al. Modulation of oxidative stress as an anticancer strategy , 2013, Nature Reviews Drug Discovery.
[14] Miran Kim,et al. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. , 2013, Journal of hepatology.
[15] Y. Mitsuishi,et al. The Keap1–Nrf2 system in cancers: stress response and anabolic metabolism , 2012, Front. Oncol..
[16] D. Torres,et al. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[17] S. Harrison,et al. Hepatitis C virus infection and nonalcoholic steatohepatitis. , 2012, Gastroenterology & hepatology.
[18] E. Chu,et al. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice , 2012, British Journal of Cancer.
[19] C. Brenner,et al. Non-alcoholic steatohepatitis: new insights from OMICS studies. , 2012, Current pharmaceutical biotechnology.
[20] D. Torres,et al. Nonalcoholic Steatohepatitis and Noncirrhotic Hepatocellular Carcinoma: Fertile Soil , 2012, Seminars in Liver Disease.
[21] M. Yeh,et al. Peroxisome proliferator‐activated receptor‐α agonist, Wy 14 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non‐alcoholic steatohepatitis , 2012, Journal of gastroenterology and hepatology.
[22] Yinghua Shen,et al. [Effects of telmisartan on nonalcoholic steatohepatitis rat model by activating peroxisome proliferator-activated receptor r]. , 2011, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.
[23] J. Muntané,et al. Human SREBP1c Expression in Liver Is Directly Regulated by Peroxisome Proliferator-activated Receptor α (PPARα)* , 2011, The Journal of Biological Chemistry.
[24] D. Haro,et al. Human HMGCS2 Regulates Mitochondrial Fatty Acid Oxidation and FGF21 Expression in HepG2 Cell Line* , 2011, The Journal of Biological Chemistry.
[25] S. Ballinger,et al. Role of reactive oxygen species in injury-induced insulin resistance. , 2011, Molecular endocrinology.
[26] F. Foufelle,et al. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP‐1c , 2010, Diabetes, obesity & metabolism.
[27] R. Xavier,et al. Wnt signaling regulates mitochondrial physiology and insulin sensitivity. , 2010, Genes & development.
[28] H. Ford,et al. Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression , 2010, Journal of Mammary Gland Biology and Neoplasia.
[29] A. Cheng,et al. PPARγ is essential for protection against nonalcoholic steatohepatitis , 2010, Gene Therapy.
[30] J. Hardwick,et al. PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid ω-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease , 2010, PPAR research.
[31] Mihee M. Kim,et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1 , 2010, Nature Cell Biology.
[32] J. Dufour,et al. Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. , 2010, Clinical science.
[33] M. Pagano,et al. Wnt signaling in mitosis. , 2009, Developmental cell.
[34] H. Yoshiji,et al. Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis. , 2009, World journal of gastroenterology.
[35] R. Kulkarni,et al. Wnt signaling: relevance to β-cell biology and diabetes , 2008, Trends in Endocrinology & Metabolism.
[36] N. Kiyosawa,et al. Species-specific regulation of PXR/CAR/ER-target genes in the mouse and rat liver elicited by o, p'-DDT , 2008, BMC Genomics.
[37] Y. Miyamoto,et al. Generation and characterization of a monoclonal antibody against NPI-1 subfamily of importin alpha. , 2008, Hybridoma.
[38] J. Hardwick. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. , 2008, Biochemical pharmacology.
[39] R. Nusse,et al. Wnt signaling and stem cell control , 2008, Cell Research.
[40] Y. Komiya,et al. Wnt signal transduction pathways , 2008, Organogenesis.
[41] R. Nusse,et al. Wnt/β-Catenin Signaling in Murine Hepatic Transit Amplifying Progenitor Cells , 2007 .
[42] Yutaka Matsuyama,et al. Staging of Hepatocellular Carcinoma: Assessment of the Japanese TNM and AJCC/UICC TNM Systems in a Cohort of 13,772 Patients in Japan , 2007, Annals of surgery.
[43] José L Sevilla,et al. Identification of a gene-pathway associated with non-alcoholic steatohepatitis. , 2007, Journal of hepatology.
[44] Hideki Yamamoto,et al. Post-translational palmitoylation and glycosylation of Wnt-5a are necessary for its signalling. , 2007, The Biochemical journal.
[45] C. McClain,et al. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. , 2007, The Journal of nutritional biochemistry.
[46] Lisa M Yerian,et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease , 2006, Hepatology.
[47] H. Stefánsson,et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes , 2006, Nature Genetics.
[48] R. Nusse,et al. The Wnt signaling pathway in development and disease. , 2004, Annual review of cell and developmental biology.
[49] J. Féher,et al. [Treatment of non-alcoholic steatohepatitis]. , 2004, Orvosi hetilap.
[50] K. Okita,et al. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. , 2004, Biochemical and biophysical research communications.
[51] G. Gores,et al. Apoptosis: The nexus of liver injury and fibrosis , 2004, Hepatology.
[52] S. Kliewer,et al. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. , 2002, Molecular pharmacology.
[53] L. Ellis,et al. Simplified staging for hepatocellular carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] S. Fukushima,et al. Formation of 8-hydroxydeoxyguanosine and cell-cycle arrest in the rat liver via generation of oxidative stress by phenobarbital: association with expression profiles of p21(WAF1/Cip1), cyclin D1 and Ogg1. , 2002, Carcinogenesis.
[55] J. Chiang,et al. Transcriptional Regulation of the Human Sterol 12α-Hydroxylase Gene (CYP8B1) , 2001, The Journal of Biological Chemistry.
[56] R. Nusse,et al. Wnt signaling: a common theme in animal development. , 1997, Genes & development.
[57] Roel Nusse,et al. Wnt genes , 1992, Cell.
[58] C. Mantzoros,et al. Leptin in nonalcoholic fatty liver disease: a narrative review. , 2015, Metabolism: clinical and experimental.
[59] H. Baba,et al. Epithelial-mesenchymal transition expression profiles as a prognostic factor for disease-free survival in hepatocellular carcinoma: Clinical significance of transforming growth factor-β signaling. , 2013, Oncology letters.
[60] S. Fukushima,et al. Mitochondrial prohibitins and septin 9 are implicated in the onset of rat hepatocarcinogenesis. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.
[61] J. Corton,et al. Characterization of peroxisome proliferator-activated receptor alpha--independent effects of PPARalpha activators in the rodent liver: di-(2-ethylhexyl) phthalate also activates the constitutive-activated receptor. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[62] Xi He,et al. Wnt/ β -catenin signaling: components, mechanisms, and diseases , 2010 .
[63] P. Paschos,et al. Non alcoholic fatty liver disease and metabolic syndrome. , 2009, Hippokratia.
[64] Brian P. Mulhall,et al. Nonalcoholic steatohepatitis , 2004, Current treatment options in gastroenterology.